Cats and Humans Share Cancer Gene Mutations — New Study Opens Door for Cross-Species Treatment

TL;DR

• What happened: Scientists mapped the genetic landscape of cancer in 493 domestic cats across 13 tumour types and 5 countries — the largest study of its kind ever conducted.
• The headline finding: The FBXW7 gene is mutated in 53–72% of feline mammary tumours, mirroring the same mutation that drives poor outcomes in human breast cancer.
• Beyond FBXW7: Three other key genes — TP53 (33% in cats vs. 34% in humans), PIK3CA (47%, already targetable with existing drugs), and KIT (40% in mast cell tumours) — show near-identical mutation rates across species.
• Treatment implications: Lab tests showed FBXW7-mutated tumours are more sensitive to specific chemotherapy drugs, suggesting cats could serve as predictive models for human treatment response.
• Environmental link: Because cats share our homes, air, and lifestyle exposures, they act as sentinel species — their cancers may provide early warning of environmental carcinogens relevant to humans.
• "One Medicine" framework: The study champions breaking the silo between veterinary and human oncology, arguing that treating cancer as a cross-species disease accelerates drug development for both.
• Open data: The full genomic dataset has been made freely available to researchers worldwide as a resource for comparative oncology.

1. The Study at a Glance

The research represents the most ambitious effort ever undertaken to understand the genetics of feline cancer. Key parameters of the study include:

The tumour types studied aligned with broad human histopathological classifications, ranging from benign growths to highly aggressive malignant tumours, including feline mammary carcinoma (MAM), cutaneous mast cell tumour (cMCT), and cancers of the blood, bone, lungs, skin, gastrointestinal tract, and central nervous system.

2. The FBXW7 Discovery: A Cross-Species Smoking Gun

2.1 What Is FBXW7?

FBXW7 is a tumour-suppressor gene that encodes a critical component of the ubiquitin-proteasome system — the cell's internal machinery for tagging and destroying damaged or unwanted proteins. When FBXW7 functions normally, it targets oncogenic proteins for degradation, acting as a brake on uncontrolled cell growth. When mutated, that brake fails.

2.2 The Numbers

In the study, FBXW7 emerged as the most frequently altered gene in feline mammary carcinomas:

• 53%–72% of feline mammary tumour samples carried FBXW7 mutations (depending on the cohort analysed)
• In human breast cancer, FBXW7 mutations are similarly associated with poorer prognosis and more aggressive disease progression
• Seven specific driver genes were pinpointed for feline mammary carcinoma; FBXW7 was the most prevalent

2.3 Why It Matters

This is not a superficial similarity. The FBXW7 mutation appears to play the same functional role in both species — disabling a tumour suppressor and enabling malignant growth. Dr. Latasha Ludwig, co-author and assistant clinical professor at Cornell University's College of Veterinary Medicine, captured the significance:

"We are now moving toward a stage where we can treat the specific mutation, not just the species or necessarily a specific tumour type. We can utilise the information that we find in people and translate that to cats, and also from cats to humans. We are no longer looking at these as separate problems, but as a shared biological challenge."

3. Beyond FBXW7: A Broader Genetic Convergence

The study revealed that the genetic overlap between feline and human cancers extends well beyond a single gene.

3.1 TP53: The Pan-Cancer Parallel

The most frequently mutated gene across all feline tumour types was TP53, appearing in 33% of all tumours studied. This almost exactly mirrors human pan-cancer studies, where TP53 mutations occur in 34% of all tumours. TP53, often called the "guardian of the genome," is the most studied tumour-suppressor gene in human oncology — and its near-identical mutation rate in cats underscores the deep biological parallels.

3.2 PIK3CA: A Druggable Target

In feline mammary tumours, PIK3CA was the second most common driver gene, mutated in 47% of cases. This is significant because PIK3CA is already a well-established drug target in human breast cancer, with PI3K inhibitors approved for clinical use. The presence of the same mutation in cats suggests these existing therapies could potentially be repurposed for veterinary oncology.

3.3 KIT and Mast Cell Tumours

In feline cutaneous mast cell tumours (cMCT), the KIT gene was identified as a key driver in approximately 40% of cases. Notably, a canine-approved KIT-targeted therapy already exists and is known to be well tolerated in cats — offering a near-term translational opportunity.

3.4 Cancer Types with Cross-Species Links

The study identified genetic parallels between feline and human cancers across the following tumour types:

• Mammary (breast) carcinoma — FBXW7, PIK3CA
• Blood cancers (leukaemia, lymphoma)
• Bone cancers (osteosarcoma)
• Lung cancers
• Skin cancers — including UV-induced squamous cell carcinoma
• Gastrointestinal cancers
• Central nervous system tumours

4. Chemotherapy Sensitivity: A Glimpse of Clinical Potential

One of the most promising findings emerged from ex vivo drug testing — experiments conducted on tumour tissue samples in the laboratory.

Researchers found that certain chemotherapy drugs demonstrated heightened efficacy against feline mammary tumours carrying the FBXW7 mutation. While these results were observed in tissue cultures and require extensive clinical validation, they represent a critical proof of concept: the genetic profile of a tumour may predict its drug sensitivity, regardless of whether the patient is a cat or a human.

Dr. Sven Rottenberg, co-senior author at the University of Bern, noted:

"Having access to such a large set of donated tissues allowed us to assess drug responses across tumour types in a way that hasn't been possible at this scale before."

This finding opens two parallel pathways:

1. Veterinary translation: Cats with FBXW7-mutated mammary tumours could become candidates for specific chemotherapy regimens, improving outcomes for a disease that is currently highly aggressive and difficult to treat in felines.
2. Human relevance: Feline clinical trials could generate data that informs human breast cancer treatment strategies, particularly for the subset of patients with FBXW7-mutated tumours.

5. The Environmental Connection: Shared Exposures, Shared Risks

A compelling dimension of the study is the environmental overlap between cats and their owners. Unlike laboratory mice — which live in controlled, artificial conditions — domestic cats share the same homes, air, water, and sometimes even food as their human companions.

Dr. Bruce Kornreich, director of the Cornell Feline Health Center, explained:

"Among the attractive aspects of studying feline cancers to learn more about human cancers is that cats are exposed to similar environmental conditions as humans — as opposed to, say, mice, a commonly used animal in biomedical research. They also suffer from many of the same diseases as humans, supporting the notion that these two species share at least some basic mechanisms of disease."

The study's finding on cutaneous squamous cell carcinoma reinforces this point. Dr. Ludwig noted that many of these feline skin cancers were associated with UV-induced radiation damage — the same mechanism that drives many human skin cancers. "That speaks to our shared environment from that perspective," she said.

This environmental dimension positions domestic cats as a uniquely valuable sentinel species for studying how environmental carcinogens contribute to cancer development in humans.

6. The "One Medicine" Framework

The study is a flagship example of the One Medicine (or One Health) approach — a philosophy that treats human and veterinary medicine as a single, integrated discipline rather than separate silos.

6.1 How It Works in Practice

6.2 The Open-Access Resource

The research team has made the entire dataset — covering 493 tumour samples across 13 cancer types — freely available to the global scientific community. This open-access database allows researchers worldwide to:

• Explore how tumours develop across species
• Compare drug responses between feline and human cancers
• Identify new therapeutic targets
• Design clinical trials that benefit both veterinary and human patients

7. What This Means for the Future

7.1 For Cats

Feline oncology has historically lagged behind canine oncology in terms of diagnostic tools and treatment options. This study changes that. As Dr. Louise Van Der Weyden, senior author at the Wellcome Sanger Institute, stated:

"This is one of the biggest-ever developments in feline oncology and means the genetics of domestic cat tumours are no longer a 'black box.' We can now begin to take the next steps forward towards precision feline oncology, to catch up with the diagnostic and therapeutic options that are available for dogs with cancer, and ultimately, one day, humans."

The immediate implications for cats include:

• Earlier diagnosis through genetic screening
• More accurate prognostication based on mutation profiles
• Personalised treatment plans targeting specific driver mutations
• Access to repurposed human cancer drugs through veterinary clinical trials

7.2 For Humans

The study positions domestic cats as a powerful and underutilised model for human cancer research. Key advantages include:

• Natural tumour development: Unlike laboratory mice, cats develop cancer spontaneously in real-world conditions
• Shared environment: Cats and humans are exposed to the same environmental carcinogens
• Genetic similarity: The conserved oncogenic pathways mean findings in cats are more likely to translate to humans
• Faster trials: Veterinary clinical trials can often proceed more quickly than human trials, generating preliminary efficacy data

7.3 For Drug Development

The FBXW7 chemotherapy sensitivity finding suggests a new paradigm: mutation-driven, species-agnostic drug development. A drug that works against an FBXW7-mutated tumour in a cat may work against the same mutation in a human — and vice versa. This could dramatically accelerate the drug development pipeline by allowing parallel testing across species.

8. Study Details and Funding

Authors and Affiliations

The study was led by Bailey A. Francis (co-first author, Wellcome Sanger Institute) and involved researchers from:

• Wellcome Sanger Institute, Cambridge, UK
• Ontario Veterinary College, University of Guelph, Canada
• University of Bern, Switzerland
• Cornell University College of Veterinary Medicine, USA
• Additional collaborating institutions across Europe and North America

Senior authors: Dr. Louise van der Weyden (Wellcome Sanger Institute), Dr. Geoffrey A. Wood (University of Guelph), Dr. Sven Rottenberg (University of Bern), Dr. David J. Adams (Wellcome Sanger Institute)

Funding

The research was supported by:

• EveryCat Health Foundation
• CVS Group (£64,000 through its research grants programme)
• Wellcome
• Natural Sciences and Engineering Research Council of Canada (NSERC)
• Swiss National Science Foundation

9. Key Takeaways

1. First large-scale feline cancer genome: This is the most comprehensive genetic analysis of cat cancers ever conducted, covering 493 tumours across 13 cancer types and 5 countries.

2. FBXW7 is the headline finding: Mutated in 53–72% of feline mammary tumours, this gene mirrors a mutation linked to poor prognosis in human breast cancer — and tumours with this mutation showed heightened sensitivity to certain chemotherapy drugs in laboratory tests.

3. TP53 mutation rates are nearly identical: 33% in cats vs. 34% in humans — a striking pan-cancer parallel that validates the cross-species approach.

4. PIK3CA offers a near-term drug target: Already targeted by approved human therapies, this mutation in 47% of feline mammary tumours could enable rapid veterinary translation.

5. Cats are a uniquely valuable model: Unlike lab mice, cats share human environments and develop cancer naturally — making them an ideal sentinel species for environmental carcinogen research.

6. Open-access data will accelerate global research: The freely available database enables scientists worldwide to build on these findings.

7. The One Medicine approach is gaining momentum: This study demonstrates that breaking down the wall between veterinary and human oncology benefits both fields — and both species.

References

1. Francis, B. A., Ludwig, L., He, C., et al. (2026). "The oncogenome of the domestic cat." Science, 391(6787), 793. DOI: 10.1126/science.ady6651

2. Cornell University College of Veterinary Medicine. (2026, February 19). "Landmark study finds striking parallels in feline, human cancers." Cornell Chronicle.

3. University of Guelph. (2026, May 24). "Scientists say house cats could help unlock new cancer treatments for humans." ScienceDaily.

4. Vet Times. (2026, March 17). "New study praised for 'one of biggest developments' in cat cancer research."

5. Bioengineer.org. (2026, February 19). "Feline Discoveries May Unlock New Insights into Human Cancer."